HOS / HOS-luc Orthotopic Mouse Model Service for Sarcoma

The HOS / HOS-luc orthotopic mouse model of sarcoma engrafts a classic human osteosarcoma line into the marrow cavity of the tibia in immunodeficient mice, where it grows as a slow, osteolytic primary tumor and ultimately seeds the lung. From authenticated cell expansion and intratibial implantation surgery to weeks-long luciferase monitoring, CT-based bone assessment and metastasis confirmation, Alfa Cytology delivers complete HOS / HOS-luc orthotopic study programs shaped around each sponsor’s timeline, compound and endpoint needs—exclusively within preclinical research.

Overview of HOS / HOS-luc Orthotopic Mouse Model for Sarcoma

HOS is among the oldest continuously cultured human osteosarcoma lines, maintained by ATCC as CRL-1543, and was isolated decades ago from a primary osteosarcoma of the distal right femur in a 13-year-old Caucasian girl. In culture the cells are elongated and polygonal, adherent as a monolayer with a mesenchymal bearing, and alkaline-phosphatase positive—yet their full osteogenic program only switches on inside organized three-dimensional matrices, since routine monolayer culture does not deposit calcium apatite. The line occupies a special place in osteosarcoma research as the parental stock from which two workhorse derivatives were raised: 143B, transformed with mutant K-ras into a fiercely aggressive, highly metastatic line, and MNNG/HOS, transformed with a chemical carcinogen and prized in chemotherapy-resistance studies. Compared with these offspring, HOS itself is comparatively restrained—a property that turns out to be advantageous in vivo.

Fig 1. Primary tumor BLI curves and IVIS SpectrumCT (BLI/CT/HES/Luc) panels of HOS and Saos-2-B parental, R/MTX and R/DOXO orthotopic CDX models at sacrifice. (Marques da Costa, Maria Eugénia, et al., 2019)

In the orthotopic format, luciferase-labeled HOS-luc cells (commonly a lentiviral Luc2 reporter, often co-expressed with a fluorescent tag) are loaded into the proximal tibial cavity of immunodeficient mice, suspended in a small volume of Matrigel that limits immediate washout into the circulation. Primary tumors engraft with 100% consistency in NSG mice but expand slowly and diffusely, showing a predominantly osteolytic profile on CT scans—bone destruction rather than the dense osteoblastic reaction seen with some other lines—while pulmonary metastases typically declare themselves around day 26 after implantation and appear as numerous but small nodules in most animals, confirmed at necropsy by ex vivo imaging and histology. Engraftment is markedly better in NSG than in nude recipients, and the protracted disease course (studies may extend beyond 100 days) suits long treatment windows and resistance-emergence designs, including the methotrexate- and doxorubicin-resistant HOS derivatives already characterized in this exact setting. The trade-offs are equally clear: the immunocompromised host rules out immunotherapy questions, and the slow kinetics demand patience and disciplined imaging schedules—both of which the luciferase readout, detectable within days of implantation, makes far easier to manage.

Cell Line Information: HOS / HOS-luc

HOS and its luciferase-labeled derivative HOS-luc descend from the same human primary tumor; the reporter line additionally stably expresses firefly luciferase (typically the Luc2 variant) for quantitative optical tracking. Key characteristics are summarized below.

Our Services

Combining meticulous bone surgery, quantitative bioluminescence and CT imaging and in-house histopathology, Alfa Cytology adapts every HOS / HOS-luc orthotopic engagement to the sponsor’s goals—setting implantation conditions, imaging cadence and endpoint panels so that even slow-burn tumor kinetics resolve into clear, decision-ready preclinical findings.

Workflow of HOS / HOS-luc Orthotopic Mouse Model Construction

Orthotopic construction of the HOS / HOS-luc model is a survival-surgery workflow performed under inhalation anesthesia with pre-emptive analgesia, aseptic technique and sustained post-operative observation, reflecting the long study horizons this slow-growing model demands. The procedure typically advances through the following stages:

1. Cell line qualification: HOS or HOS-luc vials are mycoplasma-tested and STR-verified; reporter performance is confirmed in vitro by serial cell-titer bioluminescence titration with D-luciferin before expansion.
2. Animal preparation: immunodeficient mice (NSG preferred; athymic nude acceptable, typically 6–8 weeks old) are acclimatized under appropriate containment, health-screened and randomized by body weight ahead of surgery.
3. Anesthesia, analgesia and asepsis: mice receive isoflurane anesthesia with pre-emptive buprenorphine, the surgical leg is clipped and disinfected, and a sterile field with sterile instruments is maintained throughout.
4. Surgical exposure: a small incision over the knee exposes the proximal tibia, providing access to the medullary cavity under magnification.
5. Intratibial inoculation: HOS / HOS-luc cells (typically 1.5 × 10⁶ in 10 µL Matrigel at 4 mg/mL) are injected into the proximal tibial cavity with a fine needle; the Matrigel suspension limits immediate spread into the circulation.
6. Closure and recovery: soft tissue and skin are closed with absorbable sutures and wound clips, post-operative analgesia is maintained, and gait, body weight and leg deformation are monitored on a defined schedule.
7. Longitudinal monitoring: primary tumor growth is tracked in vivo by weekly bioluminescence imaging after intraperitoneal D-luciferin for HOS-luc, with periodic CT scans documenting osteolytic bone change; given the slow kinetics, study timelines commonly extend beyond 100 days.
8. Endpoint and analysis: at termination the tibial tumor is excised and weighed, lungs and spleen are removed for ex vivo bioluminescence and metastasis counting, and tissues are processed for histology (including HES and luciferase staining), immunohistochemistry and molecular analysis.

Fig 2. HOS / HOS-luc orthotopic mouse model construction workflow.

Case Study-HOS / HOS-luc Orthotopic Mouse Model Development

Alfa Cytology curates a growing preclinical case-study collection for the HOS / HOS-luc orthotopic platform, spanning establishment-phase refinement of inoculum and implantation conditions, long-window bioluminescence and CT tracking of osteolytic primary tumors in vivo, targeted-therapy and chemotherapy-resistance intervention studies, and systematic lung metastasis quantification with histological confirmation. Illustrative materials—including imaging series, tumor growth trajectories and endpoint summaries—are available on request and are refreshed as further programs conclude.

Why Choose Alfa Cytology?

Sponsors bring the HOS / HOS-luc model to Alfa Cytology because long-duration bone-orthotopic studies reward exactly the operational strengths this team has built:

• A disciplined bone-surgery group delivering consistent, high-survival intratibial implantation.
• STR-verified HOS and stably luciferase-labeled HOS-luc banks, with resistant derivatives available on request.
• Dual-modality monitoring that pairs quantitative bioluminescence with CT documentation of osteolysis.
• Operational stamina for long-horizon studies, with structured imaging and welfare schedules beyond 100 days.
• A configurable endpoint menu spanning efficacy, ex vivo metastasis counting, histopathology and molecular analysis.
• Experience across the HOS / MNNG-HOS / 143B lineage for comparative and resistance-focused designs.
• Responsive, single-point project communication with milestone-based progress reporting.
• An exclusively preclinical mandate, with all studies designed, conducted and reported as non-clinical research.

Contact Us

If the HOS / HOS-luc orthotopic sarcoma model suits your next preclinical objective, contact us to share your compound, timeline and preferred endpoints. The Alfa Cytology team will reply with a customized plan covering model setup, imaging cadence and analysis strategy—reach out today and put your program on solid ground.

For research use only. Not intended for any clinical use.